AMGEN Inc.
NASDAQ:AMGN 3:59:59 PM EDT
| Market Cap (Intraday) | 132.85B |
| Current PE | 18.29 |
| Forward PE | 13.65 |
| 2yr Forward PE | 12.61 |
| 10-Day MA | $232.67 |
| 50-Day MA | $234.68 |
| 200-Day MA | $234.10 |
Amgen, Inc. Stock, NASDAQ:AMGN
One Amgen Center Drive, Thousand Oaks, California 91320-1799
United States of America
Phone: +1.805.447.1000
Number of Employees: 24300
Description
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.